Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK Chemical Structure

Molecular Weight(MW): 467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 96 Publications

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a Ml7ERZBweHSxc3nzJGF{e2G7 NUHJcZFvPTEQvF2= MnrxNlRp MWPpcoRq[2G2ZYOgZUBxem:2ZXP0bZZmKGWoZnXjeEBi\2GrboP0JIV1d3Cxc3nk[S=> NVPxVJVwOjZzNkmwO|U>
HGL5 NFvqSJVCeG:ydH;zbZMhSXO|YYm= M3nzWFUx|ryP NEfsRZQzPGh? NVq2ZoNOcW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV? NXO2V2I4OjZzNkmwO|U>
HepG2 MlfBRZBweHSxc3nzJGF{e2G7 MYSyNO69VQ>? M3HxUFFp M{XIc4F1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> Mom4NlYyPjR5OUW=
BEL-7402 NWTHfXM{SXCxcITvd4l{KEG|c3H5 NELmWHQzOM7:TR?= NEXReWwycA>? MlHmZZR1\W63YYTl[EB1cGViYYDvdJRwfGmlIHnu[JVkfGmxbjDv[kBKUUlvMUFCpC=> NV7pbHh2OjZzNkS3PVU>
CEF NXKxc|ZDU2mwYYPlJGF{e2G7 M4HtUVAtOzNuNkesNVAx|ryP M2TxfFE2dWmw Mk\T[I94di2{ZXf1cIF1\XNiUGKg[Y57gW2nIHHjeIl3cXS7IITvJFQx97zHIHH0JFExOM7:TR?= MWGyOlExOjN|OR?=
SP2/0 M{fPb2Fxd3C2b4Ppd{BCe3OjeR?= Mm\TNVAx|ryP M1ra[lFp NFu2N2RFVVOR NVnxOVMx[myxY3vzJJRp\SCjcH;weI9{cXNib3[gV3AzNzBiY3XscJM> M1z4RlI3ODd2N{Oy
HUVEC-2c MXjBdI9xfG:|aYOgRZN{[Xl? MmnLOVDPxE1? NETYT443cA>? NEi2fJBl\WO{ZXHz[YQhfGinIH;4MWxFVC2rbnT1Z4VlKGG3dH;wbIFogQ>? M4jTOVI3ODJzN{K5
U1 NW\v[ZZUSXCxcITvd4l{KEG|c3H5 M4Lr[VAuOTByzszN MlTiNog> M1fMbpJm\HWlZYOg[JJ2\y2rbnT1Z4VlKGGyb4D0c5NqeyCjbnSgd5Vje2WzdXXueEBJUVZvMTDy[ZBtcWOjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWGyOVk5ODl2Mh?=
ACH-2 NUn6WVZ3SXCxcITvd4l{KEG|c3H5 Mm\yNE0zODEQvF2= M4LiZlJp M3zNWpJm\HWlZYOg[JJ2\y2rbnT1Z4VlKGGyb4D0c5NqeyCjbnSgd5Vje2WzdXXueEBJUVZvMTDy[ZBtcWOjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGjsU3AzPTl6MEm0Ni=>
U1 MmDCT4lv[XOnIFHzd4F6 MmXkNVAx|ryP MkPDNog> MVjpcohq[mm2czDjZZNx[XOnLUO= MXqyOVk5ODl2Mh?=
A549/V16 M3\jdWFxd3C2b4Ppd{BCe3OjeR?= MoXWOVDPxE1? M2jaeVFp MmDydoVxemW|c3XzJHRIN1SPLXnu[JVk\WRiYYDvdJRwe2m| MmjKNlU6PDZyM{O=
SGN MX;BdI9xfG:|aYOgRZN{[Xl? M{\qSFIxdU1? M3jQSlQ5cA>? MUjoZZMhdm9iaX7mcJVmdmOnIH;uJGFKTixiY3HsdIFqdiCneIDy[ZN{cW:wIH;yJINmdGxiYYDvdJRwe2m| MljkNlU5PzR4M{O=
HCT116  NGfNdlJCeG:ydH;zbZMhSXO|YYm= MlzCOVDPxE1? MY[ybC=> NXvrW4E5cW6qaXLpeJMhfGinIHPlcIwh\GWjdHigbY5lfWOnZDDifUBFTF[S MlXiNlU5Pjh6MUi=
DTK-SME NF7mUYdCeG:ydH;zbZMhSXO|YYm= MWS1NO69VQ>? MYKybC=> NWn0OVJ2TE2VTx?= NVXpZ4JHeGG{dHnhcIx6KGmwaHnibZR{KHSqZTDhdI9xfG:|aYOgbY5lfWOnZDDifUBjfXCrdnHjZYlv\Q>? M{j3OlI2QDR|OEm3
HL-60 NFnNT2ZCeG:ydH;zbZMhSXO|YYm= Ml;jOVDPxE1? M2q2ZVQ5cA>? NWHhT2NqemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCVS1mtTWkhfHKnYYTt[Y51yqB? M2jiWFI2QDJ2MESz
U937 M1TBWmFxd3C2b4Ppd{BCe3OjeR?= NGX4R2I2OM7:TR?= NGO3To81QGh? NXfCd|hjemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCVS1mtTWkhfHKnYYTt[Y51yqB? NFvyfZozPTh{NEC0Ny=>
A549 MYTBdI9xfG:|aYOgRZN{[Xl? NWrLW29VOjBizszN M{naelI1cA>? MlzhdoVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBJTkOSIITy[YF1dWWwdB?= M17XO|I2Pzl2MUS5
HeLa MXPBdI9xfG:|aYOgRZN{[Xl? NFTHWJkyOM7:TR?= NUToe41rPDiq M1LyV4Rm[2yrbnXzJJRp\SC{YYTlJI9nKGGyb4D0c5NqeyCmcnHtZZRq[2GubIm= MUCyOVc4OjV2NR?=
SGC-7901 NWiyeGtGSXCxcITvd4l{KEG|c3H5 NIHM[XQzOMLizszN NVG0RYl1OWh? MUTpcohq[mm2czD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IH;4ZYxqeGyjdHnu MVSyOVc3PzB5Nh?=
MCF-7 NUH6VnIzSXCxcITvd4l{KEG|c3H5 M4LlcVEx|ryP Mn7PNog> MkHIbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTCzRi=> NEDiOHIzPTd{MkGxOC=>
A549 MV\BdI9xfG:|aYOgRZN{[Xl? M1L0elExKM7:TR?= NVj4bFRyOjSq M3nNUmROW09? NX\lTmtseHKxbX;0[ZMhUEKFLYTy[YF1\WRiQUW0PUBk\WyuIIP1dpZqfmGuID[gZZR1\W63YYTld{B1cGViY3zlZZZm\CCSQWLQJIV5eHKnc4Ppc44> M4\3WlI2Pjh|NU[4
U87 M1nOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnPVnJ3PTEQvF2= NX\TeYt5OWh? Moe5doVkd3[ncoOgZ4VtdCCpcn;3eIgh\nKxbTDUUXohfHKnYYTt[Y51 MWqyOVY5OTZ4OB?=
Neocortical Neuron MX3O[ZVzd3SxeHnjbZR6KEG|c3H5 M{fGVFExOM7:TR?= MoLTNYg> NHu1R3lidnSjZ3;ubZpmeyCKb3nhcYll\SCDLVnu[JVk\WRiTnX1do91d3irY3n0fS=> M33YdlI2Pjd3MECx
Primary human placental cytotrophoblasts MWDBdI9xfG:|aYOgRZN{[Xl? MkL4N|DPxE1? NIPLZnczPGh? M{TufGROW09? NV\zUldWemW4ZYLz[ZMhfGinIHnubIljcXSrb36gc4YhOTIQsj3IV2QzKGK7IITybYNtd3OjbtMg M2S2VlI2PjR{NUmy
MM NYm1N2hYSXCxcITvd4l{KEG|c3H5 MXK1NO69VQ>? NGnZPWYzOG2rbh?= MX\wZZJ1dHliaX7obYJqfHNiU1jLMYlv\HWlZXSgJINmdGxiZHXheIg> NWLSepkyOjV3M{CwPVg>
DLD1 NYW4S2lwSXCxcITvd4l{KEG|c3H5 MlLYNlDDqM7:TR?= M2TjPFFp MWjwZZJ1dHlicnX2[ZJ{\XNiY3XscEBieG:ydH;zbZMh[2G3c3XkJIJ6KFeVUEG= MWWyOVUzPDJ2Nh?=
MDA-MB-231 NIPl[5REgXSxdH;4bYNqfHliQYPzZZk> NFviTlEyOM7:TR?= M3LjUlFp NFzpUItifWevZX70d{Bk\WyuIHTlZZRpKGGodHXyJGNJXUFidILlZZRu\W62 MYGyOVUzOTVyMR?=
MKN28 MlfXRZBweHSxc3nzJGF{e2G7 MUSxNO69VQ>? MU[zNI1qdg>? MWTEUXNQ NFHPXZFqdmirYnn0d{BVVkZvzsGgdIx2eyCFSGitbY5lfWOnZDDhdI9xfG:|aYO= NEjrU3EzPTVzM{m2NC=>
HL-60 MXvDfZRwfG:6aXPpeJkhSXO|YYm= MnrNNVAx|ryP Ml\jNYg> MnTYSG1UVw>? NYnuXpNvyqCrbYDyc5ZmeyC4aXHibYxqfHlib3[gWGNPSXNvdILlZZRm\CClZXzsdy=> MmrUNlU2ODJ7M{K=
AGS MknrRZBweHSxc3nzJGF{e2G7 MnniNVDPxE1? MmD5NYg> M4TsdZBz\X[nboTzJIN2emO3bXnuMYlv\HWlZXSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[U0{NCBvODygZY5lKC17IIDyc5RmcW6| NHT1WG0zPTR7MkKxOC=>
A549  NW[zc4tMSXCxcITvd4l{KEG|c3H5 MnryNVDPxE1? MUmyOIg> Mn3KZoxw[2u|IFTNRXMucW6mdXPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiYX7kJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp MX:yOVQ{PDl6OR?=
INS-1 NEf1VI1CeG:ydH;zbZMhSXO|YYm= MVG1NO69VQ>? NHqzOnU3cA>? NGjK[mhFVVOR NYjCeVB1\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGWjcnz5JIFxd3C2b4TpZ{Bk\Wyuc9Mg MlexNlU1OzB6OUe=
Primary hepatocytes  MYnBdI9xfG:|aYOgRZN{[Xl? MYS1NO69VQ>? M2P5b|E5cA>? MlLybY5pcWKrdIOgZZBweHSxc3nzJI9nKGincHH0c4N6fGW|IHnu[JVk\WRiYomgRYN1KERiYX7kJHRPTi4QsR?= MXGyOVQxPzV|OB?=
L929-A  NVjYd2VUS3m2b4TvfIlkcXS7IFHzd4F6 MkTvNlDDqM7:TR?= M3n0XlI1cA>? MnnRbY5pcWKrdIOgWG5H|rFvaX7keYNm\CClZXzsJIRm[XSq M3XTblI2Ozl6NUSw
L929-N NWPIVJdSS3m2b4TvfIlkcXS7IFHzd4F6 NH7tZWUzOMLizszN NGO5RZQzPGh? NVHReJNx\W6qYX7j[ZMh\GWjdHigeoliKGG3dH;jdolv\SCWTldOtUBxem:mdXP0bY9v MmHnNlU{QTh3NEC=
Cytotoxicity Assay NU\HOoRPS2WubDDWbYFjcWyrdImgRZN{[Xl? NGLN[nQzOM7:TR?= MmWwOFhp MkLwdJJmfmWwdDDNTG1FNWmwZIXj[YQh[2WubDDk[YF1cA>? MVuyOVM6OjFzNh?=
COS7 M2e1eWtqdmG|ZTDBd5NigQ>? M2rtNlEx|ryP MX6yOIg> MlHEbY5kemWjc3XzJINie3Cjc3WgN{84KGGldHn2bZRq\XN? NGHVeXkzPTN6NECyOS=>
COS7 M{G0[GFxd3C2b4Ppd{BCe3OjeR?= NFezc2cyOM7:TR?= NES3Smk1QGh? NHzZT2xx[XK2aXHscJkheHKndnXueIVlKE[FMUCxMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NFrQeJMzPTN6NECyOS=>
A375 MY\BdI9xfG:|aYOgRZN{[Xl? NFnlSIg{OM7:TR?= NIC1[3gzcA>? M3;uVZBz\X[nboTzJJRp\SCmcoXnMYlv\HWlZXSgVGFTWCClbHXheoFo\Q>? MU[yOVM4PjFzNR?=
A549 MnvIRZBweHSxc3nzJGF{e2G7 NYf4OG1LPTEQvF2= MVSyOIg> MmX2doV3\XK|ZYOgdoljd3OxbXWgZolw\2WwZYPpd{BidmRiYYDvdJRwe2m|IHPheZNm\CCkeTCgR4hqcm:wZ3Thci=> NV36OHUyOjV|NEm3PFE>
A549 NWH2cZNKSXCxcITvd4l{KEG|c3H5 NGjRSmkzNjVvMkZOwG0> NXXHOINjOWh? NYPvUHh[\GWlcnXhd4V{KHSqZTDwc5B2dGG2aX;uJI9nKGGyb4D0c5Rq[yClZXzsd{Bl\XCnbnSgc44h[2:wY3XueJJifGmxboO= MV6yOVM1OjR{Nx?=
 NBL-W-S  NYK5d5VUSXCxcITvd4l{KEG|c3H5 M3TSTVUx|ryP MkXsNYg> NYDTe4E{\nWubImgdoV{[3WnczDj[YxtKH[rYXLpcIl1gSCjZoTldkBISU6WLU[xJJRz\WG2bXXueC=> MorqNlU{OjN{MkK=
Caki-1  NV3UWnQ2SXCxcITvd4l{KEG|c3H5 MX:0NO69VQ>? MXS0PIg> MYTy[YR2[2W|IITo[UBvfW2kZYKgc4YhSW6wZYjpckBXNXCxc3n0bZZmKGOnbHzz MnnUNlUzPzlzOUG=
769-P NU\ITJlLSXCxcITvd4l{KEG|c3H5 M2S3flQx|ryP NEnuOmw1QGh? MkTUdoVlfWOnczD0bIUhdnWvYnXyJI9nKEGwbnX4bY4hXi2yb4PpeIl3\SClZXzsdy=> M2TrTlI2Ojd7MUmx
H9c2 MYTBdI9xfG:|aYOgRZN{[Xl? NWLi[VBYPTEQvF2= NXzlNYdGOWh? MmnZbY5pcWKrdIOgSG9ZNWmwZIXj[YQh[2G|cHHz[UA{KGGldHn2ZZRqd25iYoX0JI5wfCC2aHWgcI9{eyCxZjDj[Yxtew>? M{TNRlI2Ojh|OEG5
K562 M1nyO2Fxd3C2b4Ppd{BCe3OjeR?= MlK0OVDPxE1? M4HpUVRp NVrHdZZicW6qaXLpeJMhUmGlLVGtbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>? M{jEZ|I2OjRzNkG5
L929 M176[GFxd3C2b4Ppd{BCe3OjeR?= MlXoNVDPxE1? MkTvOog> NVzobJJzcW6mdXPld{Bv\WO{b4D0c5NqeyC5aYToJHRPTg>? MXqyOVE6PTZ4MB?=
A549 M4XJZWFxd3C2b4Ppd{BCe3OjeR?= MnjaNVDPxE1? MnO5N4g> MmjqdoVlfWOnczDj[YxtKGGyb4D0c5NqeyClYYXz[YQh[nliUGHR MVGyOVE3OTZ7OR?=
MCF-7 MV7BdI9xfG:|aYOgRZN{[Xl? M{X3c|Ix|ryP NVLkXlZLOmh? MXjk[YNz\WG|ZYOgT2RTNXOrUl7BMYlv\HWlZXSgZZBweHSxc3nz NXq4PGw1OjVzOEKyOFA>
OS NInZXHNCeG:ydH;zbZMhSXO|YYm= MkDoNlAwPDEQvF2= M1PETlczcA>? NVn5V5pQcW6qaXLpeJMhV1NiY3XscEB3cWGkaXzpeJkhemWmdXP0bY9vKGK7IFO2JINmemGvaXTl MYqyOVE2OjN7OR?=
HUVECs NHm2c2lCeG:ydH;zbZMhSXO|YYm= M2PITFEx|ryP MV:ybC=> M1XiReKhcW6qaXLpeJMh[XCxcITvd4l{KGGwZDDmZYNqdGm2YYTld{BifXSxcHjh[5khcW5iRFXOWlIucW6oZXP0[YQhUFWYRVPz MlHCNlUyOzh5MEO=
EA.hy926 MoPQRZBweHSxc3nzJGF{e2G7 M3LFWVEx|ryP NXK3c5dFOmh? MoTaxsBqdmirYnn0d{BieG:ydH;zbZMh[W6mIH\hZ4ltcXSjdHXzJIF2fG:yaHHnfUBqdiCGRV7WNk1qdm[nY4Tl[EBGSS6qeUmyOi=> NWnGbGczOjVzM{i3NFM>
Ebs M2Ppe2Fxd3C2b4Ppd{BCe3OjeR?= NIrafFgyOC1zMEFOwG0> MYOyOIg> MWlCpG1OXFNiZ3Xu[ZJifGmxbjDyZZRmKGSnY4LlZZNm\CCjczD0bIUh[2:wY3XueJJifGmxbjDv[kB7NV[DRD7mcYshcW6lcnXhd4Vl Mn\qNlUyOzR6MUe=
Jurkat MoLzRZBweHSxc3nzJGF{e2G7 NWTzUmpTOjEQvF2= NYXU[5hUOjSq M{jFV2ROW09? NGrHcWlx[XK2aXHscJkhcW6qaXLpeEBk\WyuIHTlZZRpKG:oIFr1dotifCClZXzsd{BqdmS3Y3XkJIJ6KDFyMEW4MWY1KGOxbXLpcoVlKHerdHigWnBCyqB? MoXaNlUyOjB5MkO=
K562 MXPBdI9xfG:|aYOgRZN{[Xl? Mmf6NE4yNTIQvF2= NWjoOJFNOWh? MkSxbY5pcWKrdIOgZ4xm[X[jZ3Wgc4YhUFOSOUCgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MXmyOVEyQTF6OB?=
IMR-32 NF7iU4ZCeG:ydH;zbZMhSXO|YYm= NI\rOWs1OMLizszNxsA> NILvWFEzcA>? NILR[WNl\WO{ZXHz[UBqdiCjcH;weI91cWNiY3XscJMh[2:vcHHy[YQhfG9iVD2yJJRwgGmw MUiyOVA5PDd3NR?=
RPMI 8226 M2PRdmFxd3C2b4Ppd{BCe3OjeR?= M2jIbVExOM7:TR?= MUGxbC=> MoDhZYxud3O2IHPvcZBt\XSnbImgZoxw[2u|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JI5m[3Kxc4TheIlvNTF? MWOyOVA{Pzh3MR?=
U266  NFXVeHhCeG:ydH;zbZMhSXO|YYm= M1XXdFExOM7:TR?= MmHQNYg> NUS3eXVJeGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2x NXfYN4dwOjVyM{e4OVE>
H929  M2rlOGFxd3C2b4Ppd{BCe3OjeR?= MkfDNVAx|ryP NHHuR3YycA>? NVqyT|hNeGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2x M4TBXlI2ODN5OEWx
MM.1S  NHT1SFVCeG:ydH;zbZMhSXO|YYm= NWjMSHE6OTByzszN NXTod3N6OWh? M3fKToVn\mmlaXXueIx6KHC{ZY\lcpR{KHOxcnHm[Y5q[i2rbnT1Z4VlKGOnbHyg[IVifGhiY3;tZolv\SC5aYToJI5m[3Kxc4TheIlvNTF? MVqyOVA{Pzh3MR?=
C6 MmnERZBweHSxc3nzJGF{e2G7 MnPlOVDPxE1? NFHuOXg1QGh? MXzwdoV3\W62czD0bIUhdG:|czDv[kBk\WyuII\pZYJqdGm2eTDjZZV{\WRiYomgdJJm\26nbn;sc45m MXeyOVAyOzR5OR?=
AGS M2nJd2Fxd3C2b4Ppd{BCe3OjeR?= NWD6VXg{PTEQvF2= M2TzXlI1cA>? MlTlZYJwdGm|aIOg{tIudGGyYXPoc45mNWmwZIXj[YQh[2WubDDk[YF1cCCjbnSgbY5pcWKrdHXkJIdzd3e2aB?= MV[yOVAxQTZ7OB?=
HeLa  M4DLZWFxd3C2b4Ppd{BCe3OjeR?= NXjB[|FZPDEQvF2= MmK3NlRp MX\pcohq[mm2czD0bIUhcW6lcnXhd4VlKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IIPpVm5HOTJz M2LyfFI1QTJ6Nki1
THP-1  NV36O5pVSXCxcITvd4l{KEG|c3H5 NYLZOm9zOTEQvF2= MUSxbC=> MnzQdoVlfWOnczDhdI9xfG:|aYOgbY5lfWOnZDDifUBCVEFvU1TUxsA> M2HUVlI1QTJ|NkWz
P815  M1\qWGFxd3C2b4Ppd{BCe3OjeR?= M2LFZ|ExOCEEtV2= NWnSVVNOOTKq MnjRSG1UVw>? NEPhbG5qdmirYnn0d{B3cXK3cz3pcoR2[2WmIHHwc5B1d3Orcx?= M{\tb|I1QTJ|Mkez
HCT116 MYDBdI9xfG:|aYOgRZN{[Xl? NYHw[2J6OjEQvF2= NXPiOYhnOjSq NVTqNHR6[WK{b3fheIV{KG:oIGTRMYlv\HWlZXSgZZBweHSxc3m= MXKyOFg6ODR2OR?=
SW1116  M3\jNGFxd3C2b4Ppd{BCe3OjeR?= MXKxNEDDvU1? NIPSUoMycA>? NWnRZolvTE2VTx?= Mkn4doV{fHKjaX7zJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomg[4VncXSrbnniJJBtfXNiZHXjbZRi[mmwZR?= NVTWb3JZOjR6N{SyPFY>
LOVO MWHBdI9xfG:|aYOgRZN{[Xl? NX:4XXg3OTBiwsXN M2fIVlFp M{O3VmROW09? Ml;ydoV{fHKjaX7zJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomg[4VncXSrbnniJJBtfXNiZHXjbZRi[mmwZR?= M3TyWlI1QDd2Mki2
SNU449  MmD0RZBweHSxc3nzJGF{e2G7 NEHUTpQzOM7:TR?= NFSyUIY1QGh? MmXzSG1UVw>? NInLenJl\WO{ZXHz[ZMhdWmULUS1NU1qdmS3Y3XkJIFxd3C2b4TpZy=> Mn:xNlQ5PDF4M{i=
Caco-2 M1\IdGFxd3C2b4Ppd{BCe3OjeR?= NIjhTo41OOLCid88US=> M1HsR|Rp M3zVNZBz\X[nboTzJHNVNTdvaX7keYNm\CCcTz2xJINp[W6pZYOgZY5lKFSHUjDkdo9x NFOyWoIzPDh{MkG4Ny=>
macrophage MkGzR4VtdCCYaXHibYxqfHliQYPzZZk> MVKwMVIxOM7:TR?= NWrjT5dZOjSq MlywbY5lfWOnczDUUmYuKGGwZDDSbZA{NWSncHXu[IVvfCCwZXPyc5B1d3OrczDpckBu[WO{b4DoZYdm NWW0W5BQOjR5OUm1OlU>
AGS  MlT0RZBweHSxc3nzJGF{e2G7 Ml7NNlDPxE1? MoniNVJp NYrHSWx5TE2VTx?= MmTSdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBz\XOyb37z[UB1dyC2aHWgSZRQSWNiZoLhZ5Rqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NH33emQzPDd6OUewNy=>
LCC9  MoHIR4VtdCCYaXHibYxqfHliQYPzZZk> M4HHW|ExOM7:TR?= MkXMOYQ> MkO3Zoxw[2u|IHPlcIwh\GWjdHigbY5lfWOnZDDifUBkd22kaX7heIlwdiCOMUegZY5lKGOqbH;yc5F2cW6n NWfWPIttOjR5OEWyOVY>
U937  NIj6bI1v\WO{b4D0c5NqeyCDc4PhfS=> NWriU3Q6OTEEoN88US=> NHnJNYo{OMLibXnu NEeyRlRqdmS3Y3XzJI5m[3KxcITvd4l{KGOxbXLpcoUhf2m2aDDUUmY> NWC3fJRxOjR5N{O3OVY>
T cell NF3xV4RE\WyuIIDyc4xq\mW{YYTpc44h[XO|YYm= M3X2c|AuOTByzszN MmPMO|Jp M4L6WWlEPTB;N{Cg{txONCCrbnjpZol1eyCjboTpMWNFOy2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIHnuJHBDVUO| M{\SU|I1PzZ6N{C3
HeLa  NEfuRnVCeG:ydH;zbZMhSXO|YYm= NIPTeG42OM7:TR?= MXu3Nog> M3W1OGROW09? NXvPXphieHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3;tdI92dmS|wrCx5qCUPQ>? MlrQNlQ4PTR5OE[=
HeLa  M2G2O2Fxd3C2b4Ppd{BCe3OjeR?= M4D0eVExOM7:TR?= Ml\DNlRp MXXzeZBxemW|c3XzJJJifGVib3[gZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KG:4ZYLlfJBz\XO|aX;uJI9nKEd3OWOgc5IhTzdzUjDwNVUx\2y3ZXVCpC=> MkDENlQ4OjJ2Nki=
IEC-6  NGG0SmhCeG:ydH;zbZMhSXO|YYm= MV:xNO69VQ>? MoXENlRp MVnwdoV3\W62czDUZ4RCNWmwZIXj[YQh[2G|cHHz[U0{KGOuZXH2ZYdmKGGwZDFOtk1k[XSnbnnuJIRm\3KjZHH0bY9v M{noT|I1PzFzNUex
HCT116 MUnBdI9xfG:|aYOgRZN{[Xl? NWf0V2RwOjEQvF2= M2LpfFI1cA>? MmDFbY5pcWKrdIOgeIhmKGOnbHygZZBweHSxdHnjJIlv\HWlZXSgZpkhYUyWMkC1 NILwUpUzPDdzM{ixNi=>
L02 M{TENGFxd3C2b4Ppd{BCe3OjeR?= NH3pbmczOM7:TR?= MljmNYg> NX[1bYVMeHKndnXueJMhfGinIHPlcIwh[XCxcITvd4l{KGmwZIXj[YQh[nliTVXIVC=> NV\6RpRMOjR5ME[0OlE>
A375 MVfBdI9xfG:|aYOgRZN{[Xl? NGLtNFYzOM7:TR?= MorPNlRp MYjy[ZZmenOnczDkbYNqfHKrbn;u[UBDNWmwZIXj[YQh[XCxcITvd4l{ NGfscoEzPDZ7OUGxNS=>
HDPC M1L1SWFxd3C2b4Ppd{BCe3OjeR?= NILIbFU2OML3TR?= MoDxNlRp M1v2XIlvcGmkaYTzJG5QNWmwZIXj[YQh[XCxcITvd4l{ M2H5N|I1PjN2NUmz
A549 MVHBdI9xfG:|aYOgRZN{[Xl? MYW1NOK2VQ>? MmjsNog> MXrEUXNQ MVPwdoV3\W62czD0bIUhcHmyb3TpdIxwcWRiRF7BJINwdnSnboSgdIhie2ViaX7keYNm\CCkeTDj[ZBp[WyxY3jyc41qdg>? MmDBNlQ2QDhzM{W=
 BV-2 MVvBdI9xfG:|aYOgRZN{[Xl? NIrkTWIzOM7:TR?= M1XWTVJp M37pXZN2eHC{ZYPz[ZMhXVZvaX7keYNm\CClaILvcYF1cW5iZYj0dpV{cW:wIHHu[EBlcWyjdHnvckBw\iC2aHWgcpVkdGWjcjDlcpZmdG:yZR?= NX7u[HI4OjR3NUixNVg>
HT-29  Mnv3RZBweHSxc3nzJGF{e2G7 MWm1NO69VQ>? M{f5VVQ5cA>? NGn4doljdG:la4OgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHvh[Y1x\mW{b3y= NHHNW5EzPDV2OUG3OS=>
A549 MYjBdI9xfG:|aYOgRZN{[Xl? MWO1{txO MmXiNlRp MV3zeZBxemW|c3XzJFZmyqBqQluxNFA1OClvaX7keYNm\CCjcH;weI9{cXQEoB?= MU[yOFUzQTh5MR?=
MIA-PaCa-2 M3PaTmFxd3C2b4Ppd{BCe3OjeR?= M1e4SlI1cA>? M4\MUYJtd2OtczDjcIVifmGpZTDv[kBk[XOyYYPlMVMhcW6mdXPl[EBjgSCkb4ToJGEuPDR|NkW0JIFv\CCyYXPsbZRigGWu MWSyOFUyODl7Mh?=
Caki-1 Mk\DRZBweHSxc3nzJGF{e2G7 NW\pPGdnOjEQvF2= NFXUU44ycA>? MVPpcohq[mm2czDTR3AucW6mdXPl[EBieG:ydH;zbZM> NGTsU5czPDVyNE[4NS=>
CLL Mnz0RZBweHSxc3nzJGF{e2G7 NVnrbplYOjYQvF2= NFLJTpMycA>? MlridIFzfGmjbHz5JIJtd2OtczDNUG4zOjN6LXnu[JVk\WRiY3XscEBieG:ydH;zbZM> NV7rd4lMOjR2Nke2N|Q>
SGC-7901 MoLtRZBweHSxc3nzJGF{e2G7 NHvvPI4yOM7:TR?= M4P2PFI1cA>? M2HzVJBzd22xdHXzJJRp\SCFR1nJMYlvcGmkaYTl[EBk\WyuIHfyc5d1cCCrbjDTS2MuPzlyMTDj[Yxtew>? NFPXOYgzPDR3NES4PC=>
k1735 MmLmRZBweHSxc3nzJGF{e2G7 M17MU|Ix6oDLzszt NWn3dXBQPGh? MWfpcohq[mm2c9MgV4FtdW:wZXzsZU1qdmS3Y3XkJIFxd3C2b4Ppdy=> MnPlNlQ1PTFzMU[=
HaCaT  MXLBdI9xfG:|aYOgRZN{[Xl? NEDjWnEyODEQvF2= NUTC[5ljOWh? NGLZZYRjdHWwdIOgWXZDNWmwZIXj[YQh[XCxcITvd4l{KGmwIFjhR4FVKGOnbHzz M4G1e|I1OzV4OUm3
podocytes M4PBc2Fxd3C2b4Ppd{BCe3OjeR?= MVSyNFDPxE1? MYC2bC=> NEPrVVJqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSB|LEStSGdG MVeyOFM{Pzd5Nx?=
 KB M3nyXmFxd3C2b4Ppd{BCe3OjeR?= NX\hOJdwPTEQvF2= M2TjUlI1cA>? NXLMTZNGcW6qaXLpeJMhVGmlbz3BMYlv\HWlZXSgZ4F{eGG|ZT2zJIFv\CCSQWLQJIFkfGm4YYTpc44> MUeyOFM{PzR7Mh?=
 HepG2  Ml6xRZBweHSxc3nzJGF{e2G7 M1HMPFEx|ryP NXTKSYUzOjSq MnHBdoVlfWOnczD2bY1mdnSrbjDjcIVifmGpZTDjZZV{\WRiYomgUHBU MkTXNlQ{OjV6MU[=
fetal rat lung fibroblasts  M3vUfGtqdmG|ZTDBd5NigQ>? MV24NO69VcLi MVSxbC=> MX;pcohq[mm2czDDZZNx[XOnLUOgZYN1cX[rdIpCpC=> NF;RNJAzPDNzNEGzOS=>
PDL fibroblasts Mn\WT4lv[XOnIFHzd4F6 M{nQSlgx|ryPwrC= M4\oO|Fp M2SxRolvcGmkaYTzJGNie3Cjc3WtN{Bi[3Srdnn0feKh MonjNlQ{OTRzM{W=
MB49 NX65cXhzSXCxcITvd4l{KEG|c3H5 MoXiNlDPxE1? M4XMelFp MofudoV3\XK|ZYOgR20ucW6mdXPl[EBk\WyuIHTlZZRp MXWyOFI5OjR|Mx?=
5637 MXzBdI9xfG:|aYOgRZN{[Xl? Mn7zNlDPxE1? NWmyN2VvOWh? M1LMR5JmfmW{c3XzJGNONWmwZIXj[YQh[2WubDDk[YF1cA>? MX:yOFI5OjR|Mx?=
A549  MnS1RZBweHSxc3nzJGF{e2G7 MX[xNFDPxE1? NV;IVmo5PDiq MUTzeZBxemW|c3XzJJRp\SCjcH;weI9{cXNiY3H1d4VlKGK7IIDpdIVzcW6nwrC= NGTVV|kzPDJ5MkKwNS=>
MCC-2 MXTBdI9xfG:|aYOgRZN{[Xl? M1XIOVIxKM7:TR?= MV22bC=> NFfMOlNFVVOR MVvicI9kc3NiaX7keYNm\CCkeTDzeIF2em:|cH;ybY5mKGGyb4D0c5NqeyClZXzsJIRm[XSq M4juSFI1OjZ{NkW4
ADF NVmzV3hkSXCxcITvd4l{KEG|c3H5 NELaXXY1OM7:TR?= MXe2bC=> MVXpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBkcGWvb4To[ZJieHlicHz1d{BbdkOuMh?= M4XXXVI1OjJ6MkOy
 U373  NVLLc3h[SXCxcITvd4l{KEG|c3H5 MWW0NO69VQ>? MX62bC=> MUXpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBkcGWvb4To[ZJieHlicHz1d{BbdkOuMh?= NV7zNHlROjR{MkiyN|I>
RKO-HIPK2i MlX0RZBweHSxc3nzJGF{e2G7 NYTwNGJGPDEQvF2= Mmq4Oog> Mn3SbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2inbX;0bIVz[XC7IIDseZMhYm6FbEK= M2rqXVI1OjJ6MkOy
HEC-1B NY\OfZE5SXCxcITvd4l{KEG|c3H5 M3fCfVIx|ryP M1ThbVFp MVHy[YR2[2W|IGTQMYlv\HWlZXSgZZBweHSxc3nzxsBk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOR?= MontNlQzOTN|NUi=
4T1 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXHvUJRUOi53LUGw{txO M{e5NVRp NEnC[2pFVVOR MXvy[ZNkfWW|IITo[UBkgXSxdH;4bYNqfHlib3[gOHQyKGOnbHzzJIlv\HWlZXSgZpkhW1CGVDDpckBiKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70JI1idm6nch?= NHrGUVkzPDJyNkG2NS=>
OS  Mo\ERZBweHSxc3nzJGF{e2G7 MX:yNO69VQ>? NVPvNlgzPGh? MoTJbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiY3H1d4VlKGK7IGDEWC=> NUHTWlhVOjR{MES5N|c>
RPE M1v4OWFxd3C2b4Ppd{BCe3OjeR?= NGDZ[pYyODEQvF2= MVy0PIg> MlPMdIFzfGmjbHz5JIlvcGmkaYTzJJRp\SClYXzwZYlvNTFiYX7kJE0zKGGldHn2ZZRqd25iYYOge4VtdCCjczD0bIUh[2G|cHHz[UBi[3SrdnH0bY9v M175[|I1OjB{MEWy
UD29a NFLZVXRCeG:ydH;zbZMhSXO|YYm= M4XS[|Ux|ryP NFTzboEzPGh? M2TRVYlvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHPheZNm\CCkeTDOWXQ{ M{DUcFI1OTlyNUe0
SH-SY5Y  MXLBdI9xfG:|aYOgRZN{[Xl? NIHhd4IyOM7:TR?= MkLNNlRp NVHvSmdV[XS2ZX71ZZRmeyClYYPwZZNmKGGldHn2ZZRqd25iYX7kJINmdGxiZHXheIghcW6mdXPl[EBjgSCKTlWtNmRI MnrVNlQyPDV2NkO=
HeLa  NEPMRXFCeG:ydH;zbZMhSXO|YYm= NXLwc|QyOTBxMkFOwG0> NGDQVFIzPGh? MX7pcohq[mm2czD0bIUh[WO2aY\peJkhd2ZidHjlJI1icm:{aYT5JI9nKHSqZTDt[Y1j\XK|IH;mJJRp\SClYYPwZZNmNW[jbXnsfS=> M{XsNFI1OTN5Mk[2
SCCVII  Mm\TRZBweHSxc3nzJGF{e2G7 MWiyOe69VQ>? NYXDUlQzOWh? MWXpcohq[mm2czD0bIUh[2WubDDrbYxtcW6pIHHmeIVzKGSjc3H0bY5q[g>? MonKNlQyOjZ2NkS=
RAW 264.7 NYPhdWtxSXCxcITvd4l{KEG|c3H5 M4W1RVIx|ryP NXH5dJBNOTiq Mnn1bY5kemWjc3XzJGxEOy2LST1Otk1i[3SrbjDyZZRqdyClb33wZZJm\CC2bzDFR3RXNU2RUzD0doVifG2nboSgc45tgQ>? MWqyOFEyPjdyNx?=
A549  MWXBdI9xfG:|aYOgRZN{[Xl? M4OxNVIvPc7:TR?= MUKyOIg> Ml\L[IVkemWjc3XzJI9zcWSxbnnuMYlv\HWlZXSgZZV1d3CqYXf5JIF{KHenbHygZY5lKEyxc4Ogc4Yh|pURiH2gZYx{dyCxY3P1dpJm\CCmdYLpcoch[XW2b4DoZYdq[yCycn;j[ZN{ NU\4V5hlOjRzMEK1NlI>
UM-SCC-10A  NIXyPGJCeG:ydH;zbZMhSXO|YYm= MVq1NOK2VQ>? MUeybC=> NYnheJBpemWmdXPld{BieG:ydH;zbZMhcW6mdXPl[EBjgSCqaXfoMYRwe2ViaYPvZYxidnSxbHHjeI9v\Q>? NGXTfpQzPDB7OEe1Ny=>
BGC-823 NFTYOZpCeG:ydH;zbZMhSXO|YYm= NH7OfY8yOCEQvF2= M1L2SlI1cA>? NImzZ4Vz\WS3Y3XzJJRmfHKjbnTybY5mNWmwZIXj[YQh[XCxcITvd4l{yqB? M4i5VlI1ODl6NUGx
Nalm-6  NIDCTllCeG:ydH;zbZMhSXO|YYm= MXyyNO69VQ>? NEPRTVk1cA>? NFT5WGpqdmirYnn0d{Bk[XOyYYPlMVgh[W6mIHPhd5Bie2VvMzDhZ5RqfmG2aX;uJIFv\CCSQWLQMVEh[2ynYY\h[4U> M{K1VVI1ODN7OU[3
KHOS  NX23SFBzSXCxcITvd4l{KEG|c3H5 M4Ts[FQx|ryP M1i3e|I1cA>? NYXwSoxL[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=> M2\DO|I1ODJ3M{[x
G292 MnT4RZBweHSxc3nzJGF{e2G7 MY[0NO69VQ>? NIfQe4szPGh? MnPsZoxw[2u|IITo[UBqdmO{ZXHz[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgRmJOTDQEoB?= MlHtNlQxOjV|NkG=
MG-63 MnzlRZBweHSxc3nzJGF{e2G7 MX20NO69VQ>? NGCzWIYzPGh? MkfiZoxw[2u|IITo[UBqdmO{ZXHz[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgRmJOTDQEoB?= M3\JZlI1ODJ3M{[x
EBV-transformed B cells M3vxPWFxd3C2b4Ppd{BCe3OjeR?= MXiyNO69VQ>? NX73SVZDOmh? NEfSOFlFVVOR MUnicI9kc3NiYX70bU1ETDhyIHHu[EBidnSrLVPEPFYh[W62aXLv[JkucW6mdXPl[EBieG:ydH;zbZM> M1H6PVI1ODB6NkK4
IM-9 B MXvBdI9xfG:|aYOgRZN{[Xl? NHX2clczOM7:TR?= NYP4UZQ4Omh? NY\Ce5lOTE2VTx?= NX3qN5FY[myxY3vzJIFvfGlvQ1S4NEBidmRiYX70bU1ETDh4IHHueIljd2S7LXnu[JVk\WRiYYDvdJRwe2m| NXSybZA6OjRyMEi2Nlg>
CNE1 M{DQdWFxd3C2b4Ppd{BCe3OjeR?= NID1e5ozOM7:TR?= M{noVFQ5cA>? MYjicI9kc3NiTFutRU1qdmS3Y3XkJIFxd3C2b4Ppdy=> NUnHSnk5OjN7OEWwNlk>
CNE2 M4fwdmFxd3C2b4Ppd{BCe3OjeR?= M1K2U|Ix|ryP MVG0PIg> NVjrcIF{[myxY3vzJGxMNUFvaX7keYNm\CCjcH;weI9{cXN? MnvoNlM6QDVyMkm=
HL-60 M1;0bWFxd3C2b4Ppd{BCe3OjeR?= Ml;POVDDvU1? NHuzV5UycA>? MYTEUXNQ NELRc4FqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCEQUG0OS=> MXKyN|k1QDd3MR?=
L929 M1LJbGFxd3C2b4Ppd{BCe3OjeR?= NYHqZlJROS5{NfMAl|XDqM7:TdMg MorsNlRp M{DNN4F2\22nboTzJHRPTs7zLXnu[JVk\WRibnXjdo9xfG:|aYOgZY5lKGG3dH;wbIFogQ>? MnHUNlM6PDF5Nkm=
Jurkat NUizNpVHS2WubDDWbYFjcWyrdImgRZN{[Xl? NW\mXHhXOs7:TR?= NVK2T455PGh? NUfqWnR1emW4ZYLz[ZMh\3Kxd4ToJIlvcGmkaYTpc44h[W6mIN8yMYNifGWwaX6g[IVkemWjc3WgZpkhUFNvQWPB MWeyN|g6PjB4MR?=
RAW264.7  NFu0UVZCeG:ydH;zbZMhSXO|YYm= M1viOFExKM7:TR?= M2rKR|I1cA>? NVT1cZo3\GWlcnXhd4V{KHSqZTDhdI9xfG:|aYOgbY5lfWOnZDDifUBISQ>? NXrBZ4MxOjN6MkCyNFM>
A431  MnTjT4lv[XOnIFHzd4F6 Mmj0OFDPxE1? NYW0d|lXOmh? M{L6TYJtd2OtczDmbZNmfGmwLXnu[JVk\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgZY5lKFCDUmC= MVmyN|gxODB3OB?=
Jurkat M3LHfGNmdGxiVnnhZoltcXS7IFHzd4F6 NIj1U5gzPS1zMEFOwG0> NG\tWpM3cA>? MX7pcohq[mm2czD6MWZCNUOPSz3pcoR2[2WmIHPlcIwh\GWjdHi= MoW4NlM6OzN3M{K=
COS-7  NFftbZNHfW6ldHnvckBCe3OjeR?= M4nMdVUxyrWP M1HQ[|I1cA>? M{T4eYFn\mWldIOgeIhmKHC{b3Pld5Nqdmdib3[gRXRPOXNid3n0bEBxd2y7UTD0doFkfHN? M1nRXlI{QTN|MkC4
CAL27 M1uwVGFxd3C2b4Ppd{BCe3OjeR?= NHrobYsyOCEQvF2= NIGybXMzcA>? M1XndJN2eHC{ZYPz[ZMhS3W{LV7Qd{1z\WS3Y3XkJJZq[WKrbHn0fUBjgSC3cDD0c{A6OCV? Mlj3NlM6OTd|OU[=
THP-1  NUT1cIc2SXCxcITvd4l{KEG|c3H5 NX3MWmw5OTBvNUFOwG0> NIDTU2czcA>? MnrLbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhfHKrcITvcIll\Q>? MkD4NlM6ODB{OUm=
K562 MmrqRZBweHSxc3nzJGF{e2G7 NWX5U|ZbOjEQvF2= NUfEeHJHPDiq NFvDUZNqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSB2LV3V MUKyN|g4Pjh{Nh?=
HL-60 NIjMZmFCeG:ydH;zbZMhSXO|YYm= NYjHdZZYOTByzszN Mlm0NlRp M4PhU4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGGkaXX0ZY5mKGSrdHXydIVv\XQEoB?= M2[xblI{QDZ3N{e4
HeLa  MYrBdI9xfG:|aYOgRZN{[Xl? M1GycVIx|ryP M{fVWVJp M3viXIlvcGmkaYTzJGROVVBiaX7keYNm\CCjcH;weI9{cXN? M1zkWFI{QDZ|OU[2
U251 MWrBdI9xfG:|aYOgRZN{[Xl? M{PWZlIx|ryP M{[5[VI1cA>? NInZPWFqdmirYnn0d{Bk[XO2aXPpckBqdmS3Y3XkJGczN01icHjhd4Uh[XK{ZYP0JIFv\CCjcH;weI9{cXN? MoL2NlM5OTZ6MU[=
HL-60 MkDKRZBweHSxc3nzJGF{e2G7 MnjrOVDDvU1? NXyzSWN5PGh? NWraVI5F[myxY3vzJJRp\SClbHXheoFo\SCxZjDjZZNx[XOnLUOsJE06NCCjbnSgVGFTWCCrbnT1Z4VlKGK7IE\z M2exOFI{QDB2N{C2
Ec-109 NVfMVIg{SXCxcITvd4l{KEG|c3H5 NWHEWlhSOTBizszN NWHX[HFHPDiq MkfRdoVxemW|c3XzJHBGNW2nZHnheIVlKEWlLUGwPUBk\WyuIHHwc5B1d3Orcx?= Mk\4NlM4QDJ4NEG=
RKO NF35b5BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHHHdWwyOCEQvF2= MnzjNlRp Ml3YbY5pcWKrdIOgeIhmKGSnY4LlZZNmKG:oIHPlcIwhfmmjYnnsbZR6KGOjdYPl[EBjgSCGQVK= M4TUUFI{PzV6ME[0
T98G MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYXPN5pxOS1zMEFOwG0> MnjSNlRp Mn7qbY1xem:4ZYOgZ4VtdCC4aXHibYxqfHliY3;0doVifG2nboSge4l1cCCWUx?= NWG2SVhJOjN5NkmyO|U>
Jurkat NXfvO5RrS2WubDDWbYFjcWyrdImgRZN{[Xl? NWT6dos2OTByLUKwNO69VQ>? NWHwcHBZOjSq NXHPeHExcW6qaXLpeJMhUGGDNDDpcoR2[2W|IHHwc5B1d3OrczDk[ZBmdmSnboSgc4Yh[2:wY3XueJJifGmxbtMg Mk\tNlM4OzJ2OEG=
Molt-3  MYfBdI9xfG:|aYOgRZN{[Xl? NFnT[Ww2OM7:TR?= M1S0ZVJp NX7UTVJRemWmdXPld{Bu\WyjdH;ubY4ucW6mdXPl[EBieG:ydH;zbZM> NX3wdGNkOjN5MkWwNVM>
hMSC12 NXe3N5RRSXCxcITvd4l{KEG|c3H5 M3nIT|ExOM7:TR?= MlTGOIQ> NGjFRXJqdmirYnn0d{Bwe3Snb3flcolkKGO3bIT1doUucW6mdXPl[EBk\WyuIHTlZZRpKGGwZDDjZYxkcW[rY3H0bY9v M4nrTFI{PjV5OEKy
HM7  NFezZnNCeG:ydH;zbZMhSXO|YYm= NXHLSGZFOjEQvF5CpC=> NVjMOZpUOWh? NH3QTJNjdG:la4OgZZBq[3WuYYLlckBCKGGlZYTheIUucW6mdXPl[EBk[XOyYYPlMVMh[WO2aY\heIlwdiCjbnSgVGFTWCClbHXheoFo\Q>? MnW0NlM2QDN2MUK=
Hep-2  M2jX[WFxd3C2b4Ppd{BCe3OjeR?= MmfXNlDPxE4EoB?= MVeyOIg> NE\mVoVFVVOR NVXsUXBV[WyuZY\pZZRmeyC2aHWg[IVkemWjc3Wgc4Yh[2WubDD2bYFjcWyrdImgbY5lfWOnZDDifUB{cWyrYnnubY4> MnXsNlM2QDByM{K=
HSCs Ml3HRZBweHSxc3nzJGF{e2G7 MWm1NO69VQ>? NF76O2ozPGh? NGjLbWFFVVOR NFLkPGFqdmirYnn0d{BvcWyxdHnubYIucW6mdXPl[EBFVkFiZHHtZYdmKGmwZHnjZZRm\CCkeTDQRXJRKGOuZXH2ZYdm Mn3YNlM1QTl6N{S=
HL-60  MXvDfZRwfG:6aXPpeJkhSXO|YYm= NEDDVIczOM7:TdMg NXKyVINTOjSq NWnEfphpemWmdXPld{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDFdpk2 NGnhR24zOzR7NES4NC=>
HA MX7BdI9xfG:|aYOgRZN{[Xl? NUGzcolXPTEQvF2= MoHNNlRp NUXDfIhJe3WycILld5NmeyC2aHWgZ4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G|cHHz[U0{NCBvNzygZY5lKC17IHnu[JVk\WRiYomgZo9zfGW8b33pZk9USUiD NYL0do56OjN2N{W5OVY>
C666-1 Mmq5RZBweHSxc3nzJGF{e2G7 MmTyOVDPxE1? NEn5N5EzPGh? NIfNVnF{fXCycnXzd4V{KHSqZTDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMtKC15LDDhcoQhNTliaX7keYNm\CCkeTDic5J1\XqxbXniM3NCUEF? MWiyN|Q4PTl3Nh?=
Hepa1-6 M1K3ZWFxd3C2b4Ppd{BCe3OjeR?= NG[xPGw2OM7:TR?= MVGybC=> Mk\DbY5pcWKrdIOgZ5Vz[3WvaX6gZY5lKHKnc4\ldoF1em:uLXnu[JVk\WRiYYDvdJRwe2m| M2\T[|I{PDR4N{Wz
PLC/PRF/5c NWjxcZZ1SXCxcITvd4l{KEG|c3H5 M17tTVUx|ryP NVi2bnVtOWh? NGL3fFhxemW4ZX70d{BieG:ydH;zbZMhfHKrZ3fldoVlKGK7IFPJUi=> MUiyN|Q{QDh{NB?=
HCT116 NV[5[lBDSXCxcITvd4l{KEG|c3H5 NHXqO4oyODEQvF2= NWLhWWtsOS53aB?= MUDpcohq[mm2czDPd{1qdmS3Y3XkJINmdGxiZHXheIg> NGPEVVUzOzd2NEO1Ny=>
HCEC M3vTcmZ2dmO2aX;uJGF{e2G7 M3zGWVUx|ryP NXTLXXpRPzKq M1frUGROW09? MmqwdoV{fG:{ZYOgc4YhfGinIH7vdo1idCCKQ1XDJJBp\W6xdInw[S=> NWPMdHN2OjN5NEKwNVE>
Primary rat cerebral cortical neurons NXLjV3ZESXCxcITvd4l{KEG|c3H5 NEjVSo8yODEQvF2= NIXm[IkycA>? MYTwdoV3\W62czDD[E1qdmS3Y3XkJIFxd3C2b4Ppd{BidmRiY3XscEBl\WG2aB?= NGLDTpczOzd2MUOxOy=>
MDA-MB-231  MWrBdI9xfG:|aYOgRZN{[Xl? M1POXFI2|ryP NYPOOZNMOjSq NGjYVIxi[nKxZ3H0[ZMh[3m2b4TvfIlkcXS7IHHu[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDS[|M> Mn3SNlU{Ozd3NES=
NLRP3-Tet-on-MC/9  NHLmdoRCeG:ydH;zbZMhSXO|YYm= NH3WO4gyOC12MN88US=> MV:xNog> MojVZZR1\W63YYTld{B1cGViY3XscEBl\WG2aDDjZZV{\WRiYomgR2FRWy2jc4PvZ4lifGWmIF7MVnA{KG23dHHueJMhcW5idHjlJHRmfC2xbjDzfZN1\W1? NFjpO5kzOzdyM{O4PS=>
KNS42  NXu0fpBySXCxcITvd4l{KEG|c3H5 NU\ae4MyPTEQvF2= MYOxbC=> M2PGWZJm\HWlZYOgZ4VtdCCmZXH0bEBidmRiY3;tdIxmfGWueTDhZo9tcXOqZXSgZ4F{eGG|ZTCzM|ch[WO2aY\peJkhcW5icnXzdI9ve2VidH:gRWJVNTJ4Mz:ySGcwdWW2Zn;ycYlvKGOxbXLpcoF1cW:w NV;kS|BHOjN4OUGxOFU>
MCF-7  MXPBdI9xfG:|aYOgRZN{[Xl? MX:yNO69VcLi NHnUc3Y4Omh? NXrlb4Y2cW6qaXLpeJMh\XG3b3ytJIFv\CB2LV;IWE1u\WSrYYTl[EBieG:ydH;zbZM> MknGNlM3PzV4NEO=
hCMEC/D3  M3[1RmFxd3C2b4Ppd{BCe3OjeR?= NGfz[3MzPc7:TR?= M3nTO|czcA>? MWHy[YR2[2W|IFz0fGEhcW6mdXPl[EBieG:ydH;zbZM> NHPoT3EzOzZ4NUG5PC=>
Jurkat NH7ySW9CeG:ydH;zbZMhSXO|YYm= NFjKfZMyOi53LUWw{txO MoT6NYg> M3ntPIRwe2ViZHXw[Y5l\W62bImgd5VxeHKnc4Pld{BUWEhvaX7keYNm\CCSYYKtOEBkdGWjdnHn[UwhWEGUUDDjcIVifmGpZTygSG5CKG[{YXft[Y51[XSrb36sJIFv\CCub4PzJI9nKH[rYXLpcIl1gQ>? M{X6elI{PDR{OUe2
CNE-1 MUPBdI9xfG:|aYOgRZN{[Xl? MUGyNO69VcLi MVSyOIg> NGXZTWNqdmirYnn0d{BTSURyMEGtbY5lfWOnZDDj[YxtKGSnYYTo NHf4OGozOzR{Nki1NC=>
HONE-1 M4GyOmFxd3C2b4Ppd{BCe3OjeR?= MUCyNO69VcLi NFvQfYQzPGh? MUTpcohq[mm2czDSRWQxODFvaX7keYNm\CClZXzsJIRm[XSq MVyyN|QzPjh3MB?=
astrocytes cell Ml75RZBweHSxc3nzJGF{e2G7 MkLJOFDPxE1? M{L6O|Zp NVLlWG5MemWmdXPld{Bm[XKueTDhdI9xfG:|aYOgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6n MmLJNlM1OTF5N{i=
U-937 Mmm0RZBweHSxc3nzJGF{e2G7 MUGxNO69VQ>? NGO5dGw{OG2rbh?= M4PnOZBz\X[nboTzJHRPTi2rbnT1Z4VlKG6nY4LvdJRwe2m| NV3MV41IOjN2MUC3OFg>
MDA-MB-231 MonKRZBweHSxc3nzJGF{e2G7 NX\4UVQ3OTByzszN NETVe5gycA>? MX3pcohq[mm2czDz[Y5{cXSrenH0bY9vKHSxIGTSRWlNKHWyb36gUXRFUCCmb4fuMZJm\3WuYYTpc44> NFXUO2EzOzRyOESyPS=>
HeLa  MWrBdI9xfG:|aYOgRZN{[Xl? NYL6TGtiOTByzszN NVuwemdvOmh? NHTXdlJjdG:la4OgTnJUNTF3IFnu[JVk\XNiQYDvdJRwfGmlIFPlcIwhTGWjdHi= MXSyN|M1PDB2NR?=
Ec109 M1X6OGFxd3C2b4Ppd{BCe3OjeR?= NIHr[I0yOM7:TR?= M4TZd|Zp MXzicI9kc3NiYYDvdJRwfGmlIHPvcYJqdmG2aX;uJI9nKFSjdD3TcYFkVjdiYX7kJJJi\GmjdHnvci=> MYmyN|M{QDV4OB?=
H460  NIraUYRCeG:ydH;zbZMhSXO|YYm= NYDhNmc6OTEQvF2= NIjSR5o3cA>? Ml;4Zoxw[2u|IHHwc5B1d3SrYzDjc41jcW6jdHnvckBw\iCWYYStV41i[055IHHu[EBz[WSrYYTpc44> M1XpVVI{OzN6NU[4
HeLa  M{P3[mFxd3C2b4Ppd{BCe3OjeR?= NVjJXXRTPTEQvF2= MmHpNU42cA>? MmXaZYJzd2ejdHXzxsBEcGyjbYnkbYEucW6mdXPl[EBieG:ydH;zbZM> NUe2RnkyOjN|MEO4NFQ>
SK-HEP1 MnLZRZBweHSxc3nzJGF{e2G7 M{HjcVExOM7:TR?= M2\QR|Fp NVTCU4Q6cW6qaXLpeJMhS3KWMTDhZ5RqfmG2ZXSgZ4F{eGG|ZT2zMEAuPyxiLUisJE06NCCjbnSgdI9tgSiDRGCtdoljd3OnKTDwc4x6dWW{YYPl NX7yd|M5OjN|MEK2OVA>
QGY7701 MmrDRZBweHSxc3nzJGF{e2G7 NFy0cpQzPc7:TR?= MUOxMlVp MnLJbY5pcWKrdIOgZYNkfW23bHH0bY9vKG:oIIP1Zk1IOSCyaHHz[UBqdmS3Y3XkJIJ6KESRWDCrJJF2\XKlZYTpci=> NYXINGpWOjN{NECwOlE>
HepG2 M1nYeGFxd3C2b4Ppd{BCe3OjeR?= NX3weYVJOjEQvF2= MoPtN|BucW5? MVrpcohq[mm2czD0bIUh\W6qYX7j[YQh[2WubDDk[YF1cCCkeTDjc41jcW6nZDD0doVifG2nboSgc4Yh[XCrZ3XubY4h[W6mIGTSRWlN NEn1TVMzOzJ{NEKzPS=>
U87  M1LGVGFxd3C2b4Ppd{BCe3OjeR?= NELBSpkzPc7:TR?= MVGybC=> NGflRWll\WO{ZXHz[ZMhcXOxbHnxeYlzcXSrZ3XubY4hMEmVTDmtbY5lfWOnZDDhdI9xfG:2aXOgZ4VtdCCmZXH0bEwh[nW2IH7veEBv\WO{b4TpZ{Bk\WyuIHTlZZRp MUmyN|IzQTZ{Nh?=
HSC-2 Mlr1RZBweHSxc3nzJGF{e2G7 Ml\3NlUwPTEQvF2= NEm0UlcycA>? NGTBfmFqdmirYnn0d{BUVi1|OD3pcoR2[2WmIHP5eI91d3irY3n0fS=> NUO4R4VMOjNzNUWyOFg>
HSC-4 M3fpPWFxd3C2b4Ppd{BCe3OjeR?= NXr3VGhYOjVxNUFOwG0> MoPjNYg> M1HkfIlvcGmkaYTzJHNPNTN6LXnu[JVk\WRiY4n0c5RwgGmlaYT5 NEnZRnMzOzF3NUK0PC=>
CL-1 NILEbFNCeG:ydH;zbZMhSXO|YYm= MXqyNO69VQ>? MoPtNYg> MWXicI9kc3NiT2C0OFkhcW6mdXPl[EBk\WyuIHTlZZRp NXXhcJVzOjNzM{G3PFI>
MEL NHfoVYRCeG:ydH;zbZMhSXO|YYm= NF3aNmEzOM7:TR?= NYL5S2piOjSq NUf5W3AxTE2VTx?= NHLhfllqdXCjaYLld{BROlh5LXnu[JVk\WRiTVXMJINmdGxiYYDvdJRwe2m| NFqyUWkzOzBzNEi4Oy=>
Bel-7402  M1;3eWNie3Cjc3WgRYN1cX[jdHnvckBCe3OjeR?= MVW1NO69VQ>? M1;3fVJp M3XReIlvcGmkaYTzJHBETS2rbnT1Z4VlKGGwb3nrbZM> NIPMTFEzOzByOEe0Ni=>
Eca-109 NYL1U2tsSXCxcITvd4l{KEG|c3H5 MV2yOe69VQ>? NWDyS|VYOzCvaX6= NIHLXGpqdmirYnn0d{BDUi2EMUGtbY5lfWOnZDDj[YxtKGSnYYTo NWqye3ZpOjNyN{[5Olc>
MEL NUXrV|cxSXCxcITvd4l{KEG|c3H5 MofhNlDPxE1? MkHINYg> MoHpSG1UVw>? M3\3SYlueGGrcnXzJHAzYDdvaX7keYNm\CCPRVygZ4VtdCCjcH;weI9{cXN? M2nseVI{ODF2OEi3
Bel-7402  NEXh[HRCeG:ydH;zbZMhSXO|YYm= MXO1NO69VQ>? M4LjOlJp MX;pcohq[mm2czDQR2UucW6mdXPl[EBidm:ra3nz M2PwfFI{ODB6N{Sy
L929 MlLUSpVv[3Srb36gRZN{[Xl? M{\zfVIvPc7:TR?= NXi0bZdoOWh? NIXUW3BqdmO{ZXHz[ZMhWkmSMTDlfJBz\XO|aX;uJIFv\CCneHHj[ZJj[XSnZDDUUmbPuS2rbnT1Z4VlKG2rdH;jbI9v\HKrYXyg[Jl{\nWwY4Tpc44h[W6mIGLPV{Bxem:mdXP0bY9v NYfzNWpkOjNyMEC1NVg>
RCC  NHPT[oxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVSxNFDPxE1? MlX5NlRp MoTWdoVkd3[ncnXzJJRp\SC4aXHibYxqfHlib3[gZ4VtdHNiZYjwc5Nm\CC2bzCxOYQuWEeMMh?= MkPiNlI6QTF2OUS=
NB2a/d1 M2jTcmFxd3C2b4Ppd{BCe3OjeR?= MUixNFDPxE1? MYS3Nog> NXz4[3RZ[XS2ZX71ZZRmeyC|dHH1do9{eG:{aX7lMYlv\HWlZXSgZ4F{eGG|ZTDhZ5Rqfmm2eTygVGFTWCxiYX7kJJRifSClbHXheoFo\Q>? NVLYSYNiOjJ7OEi1OFE>
T cell M1vN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqyOU0yODEQvF2= NUj2bnVjOjSq MYHkc5NmNWSncHXu[IVvfGy7IHnubIljcXSnZDDUJINmdGxicILvcIln\XKjdHnvckBu\WSrYYTl[EB1cHKxdXfoJJRp\SClbz3zeIlufWyjdHnvckB4cXSqIHHueIkuS0R|IHHu[EBidnSrLVPENlg> M3fCdVIzQTh{NUO4
K562 NUGxW3NoSXCxcITvd4l{KEG|c3H5 MWKxNFDPxE1? MUKxbC=> MXzicI9kc3NiQXLuc4Jifmm|Y4XtxsBHNWmwZIXj[YQh[XCxcITvd4l{ NWLHTXZFOjJ7N{KzO|I>
Jurkat  MnrSRZBweHSxc3nzJGF{e2G7 NI[1XJQ1OM7:TR?= M13zfFFp NXnlTpoz[WKxbHnzbIV{KE[jc1ytbY5lfWOnZDDjZZNx[XOnIHHjeIl3[XSrb36gZY5lKGOnbHyg[IVifGh? NUDTZnlROjJ7NEK3N|g>
BGC-823 MWjBdI9xfG:|aYOgRZN{[Xl? Ml;NNVAx|ryP M2O1[VFp NGqydFBx[XK2aXHscJkhemW|Y4Xld{Bk\WyuczDh[4FqdnO2IHThcYFo\SCxZjDkZYllgmWrbh?= MmXFNlI6OjZ3NEW=
Hep3B NUe5SVZWSXCxcITvd4l{KEG|c3H5 MlPROVDPxE1? Ml3ENYg> NFjyZoNjdG:la4OgZZBweHSxc3nzJIlv\HWlZXSgZpkhUEWJQ4O= NHvyTnozOjl{M{G1OC=>
LLC-PK1 MX7BdI9xfG:|aYOgRZN{[Xl? NYnCNXVGOjEQvF2= MlTPNYg> MWnwdoV3\W62czDjbZNxdGG2aX6tbY5lfWOnZDDk[Ydz[WSjdHnvckBw\iCDdHe1MEBj\WOuaX6tNUwh[W6mIFH0[|EzKHC{b4TlbY5{ NGnWTIMzOjh7NkCzOy=>
A549 NXLhclBKSXCxcITvd4l{KEG|c3H5 NIHNNWI2OM7:TR?= Mon3NYg> MnKwZoxw[2u|IITo[UBDSUlvaX7keYNm\CCjcH;weI9{cXQEoB?= NX\3V3cyOjJ6OEeyNVU>
SGC-7901  NX3v[oVUSXCxcITvd4l{KEG|c3H5 MXSxNO69VQ>? M{eyVlI1cA>? MkPlbY5pcWKrdIOg{tIt|rJvZHnt[ZRpgWyjY4L5cJNpcWuxbnnuMYlv\HWlZXSgZZBweHSxc3nzxsA> M33kfVIzQDR6NUm3
DM6 NVLVPYx3SXCxcITvd4l{KEG|c3H5 MmLQNVAx|ryP MUi3Nog> M3q2VIJtd2OtczDic5RpKEV{Rj2xJIFv\CCHMl\0dk1u\WSrYYTl[EBkgXSxdH;4bYNqfHl? MXeyNlgzPTN{OB?=
MCF-7, MDA-MB-468, Caco-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K5V|Ux|ryP MlfsOFhp MmPobY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnubIljcXSrb36gbY5lfWOnZDDifUB{[XCxbnnu M4\TeVIzQDByOU[4
A2750  NH34UFdCeG:ydH;zbZMhSXO|YYm= NVrQWod1OjEQvF2= M2XRZ|Jp M1LUN2ROW09? NFzNO29jdG:la4OgZ4F{eGG|ZTDjcIVifmGpZTDkeZJqdmdiaHXs[Y5idGmwIITy[YF1dWWwdDDhcoQhemWmdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? NEKz[mkzOjd6NEO2Ny=>
U87  M121U2Fxd3C2b4Ppd{BCe3OjeR?= NVvC[pJlOjEQvF2= NFXEUVgzPGh? MXzy[YR2[2W|IITo[UBieG:ydH;zbZMhemG2ZTDpcoR2[2WmIHL5JHBNSUJ? NFTjN5EzOjd5OEe4NC=>
HT1080 NYXJUpRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jPRlUx|ryP M{XqXldl M336N4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpcohq[mm2aX;uJINifXOnZDDifUBkd22kaX7l[EB1emWjdH3lcpQhd2ZiRFPBJIFv\CCRTWC= NW\YZ5E{OjJ5NEC5PFQ>
A549  NIS3dGhCeG:ydH;zbZMhSXO|YYm= NXSxUpB7PTEQvF2= MmS0Nog> M1zp[JBienSrYXzsfUBl\WO{ZXHz[ZMhe2:maYXtJJNmdGWwaYTlMYlv\HWlZXSgZZBweHSxc3nz NWWwdIc3OjJ5MkG4NFQ>
Primary OPC MmW0RZBweHSxc3nzJGF{e2G7 M{XwSVHPxE1? NVTjOlBnPmhxMkTo MXLy[YR2[2W|IITo[UBx\XKlZX70ZYdmKG:oIHPlcIx{KGmwIHXhdox6NSCjbnSgcIF1\S2jcH;weI9{cXNxbnXjdo9{cXN? MX[yNlcxPzN6NR?=
PMNs M1\BUmFxd3C2b4Ppd{BCe3OjeR?= MYW0NO69VQ>? MlnZOog> MWfEUXNQ M1zFeZJmfmW{c3XkJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CClYYPwZZNmNTNidH:gcoVieiC4ZXjpZ4xmKGyndnXsdy=> MorXNlI3QTJ3N{e=
A549  MVTBdI9xfG:|aYOgRZN{[Xl? MnLoOVDPxE1? MWCxbC=> MlOwdJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSmGxaIXvd4ll\SCL MUKyNlY5PzZ|NR?=
AGS NEHwfI5CeG:ydH;zbZMhSXO|YYm= NEe1b2wzOM7:TR?= M2LvTlEzcA>? M2TqUIlvcGmkaYTzJJRp\SCjY4TpeoF1cW:wIH;mJJBzdy2lYYPwZZNmNTNiaX6gdoV{eG:wc3WgeI8hfGinIFX0U2FkKG[{YXP0bY9v MkOxNlI3QDd|OUi=
shC9  NV3EcZR6SXCxcITvd4l{KEG|c3H5 NIr1NZMyOM7:TR?= M3vQXlE3cA>? MV3icJVvfHNiU1jIJIV5eHKnc4Ppc44hcW5ic3jDPUBk\WyuczDlfJBwe2WmIITvJIVqfGincjDQRUBweiCOUFO= MViyNlY1OTB7NB?=
primary MEFs MlewSpVv[3Srb36gRZN{[Xl? NHSwVZoyOmh? M1To[:KhcW6lcnXhd4V{KGW2b4Dvd4ll\S2rbnT1Z4VlKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWg[IVxd2yjcnn6ZZRqd25? Mki3NlI3OTN5Nke=
3T9 MEFs NHjyS3RHfW6ldHnvckBCe3OjeR?= MVWxOog> M4fueYlv[3KnYYPld{BkgXSxY3jyc41mKGNicnXs[YF{\SCjZoTldkBmfG:yb4Pp[IUufHKnYYTt[Y51 M3TH[FIzPjF|N{[3
3T9 MEFs MUXGeY5kfGmxbjDBd5NigQ>? MlW1NVhp NHnmbWR2eHKnZ4XsZZRmeyCrbnn0bYF1d3JiY3HzdIF{\S17IHL1eEBld3ewcnXneYxifGW|IHXm[oVkfG:{IHPhd5Bie2W|IHHmeIVzKGW2b4Dvd4ll\SC2cnXheI1mdnR? Ml6yNlI3OTN5Nke=
MDA-MB-231  M1;UemFxd3C2b4Ppd{BCe3OjeR?= NUf6VmtIOjEQvF2= NX7BN4tRPGR? NFH4[Idz\WS3Y3XzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KG2ndH\vdo1qdiC2cnXheI1mdnRid3HzJJNq\26rZnnjZY51dHl? NGmydJEzOjV7M{S0NS=>
C6  M4rFRWFxd3C2b4Ppd{BCe3OjeR?= NFrkZnkyOM7:TR?= NF7yUoczPGh? NH62U3BjdG:la4OgeIhmKHO3cIDy[ZN{cX[nIHXm[oVkfCCxZjD0bIUheGWydHnk[UBwdiC4aXHibYxqfHl? MYeyNlU5QDl6MB?=
HL-60  Ml73RZBweHSxc3nzJGF{e2G7 NITuS20yODEQvF2= M1\mOFI1cA>? NUjpUHo{cW6qaXLpeJMhfGinIHPlcIwh[XCxcITvd4l{KHOnbHXjeIVlKChtKT3t[Y51cHmuIN8yMUgy6obUNjmt[IlodHWlb4D5doFvd3OrZHZCpFU> NWrCPY5VOjJ3NE[2Olk>
HL-60 NXfTOXA5SXCxcITvd4l{KEG|c3H5 NEXSZVYyOC16MN88US=> MlfqOIg> NF\KTHZqdmirYnn0d{BVT0iTLXnu[JVk\WRiY3XscEBieG:ydH;zbZPDqA>? NIXGbZMzOjV{M{KyPS=>
BCC MkDnRZBweHSxc3nzJGF{e2G7 M3HhOFUx|ryP M4m4cVFp NGXmbHVqdmirYnn0d{BFSVSVLX3l[IlifGWmIHfyc5d1cCCrbnjpZol1cW:w NFjiNngzOjVzOUSzOi=>
RAW 264.7 MoP3RZBweHSxc3nzJGF{e2G7 NYH6ZXFnPTBxMUCw{txO NYK1SI5{OWh? Mln5Z49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7obYJqfHNiRF;OMYlv\HWlZXSgdnJPSSClbHXheoFo\Q>? Mn;INlI1QTF2Mk[=
K562 Ml7iRZBweHSxc3nzJGF{e2G7 NH7WcpEzPc7:TR?= NH\CSpgzcA>? MkX2dJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[29vdILlZZRu\W62IIfpeIgh[W23cnXud4lvKEdiYX7kJHRTSUmO NV;OeJprOjJ2OEO3O|c>
SGC-7901 NXPWeIxjSXCxcITvd4l{KEG|c3H5 M3jYSVIxKM7:TdMg M{TUdFJp MUHheJRmdnWjdHXzJGgzVzMEoH;yJHRPTiEQsT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{KGG|IIflcIwh[XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= NV31NGNGOjJ2N{G1PFk>
PC3 M4\Q[GFxd3C2b4Ppd{BCe3OjeR?= MoPyNVDPxE1? MXW0bC=> NI\WTpNkd3WwdHXyd{BndGG4b3PvfIllNWmwZIXj[YQh[2G|cHHz[U1z\WyjdHXkJIFxd3C2b4Ppdy=> MVGyNlQ4OTl5NB?=
SMMC-7721 NXSwNFJ6SXCxcITvd4l{KEG|c3H5 NFj2d|U2OM7:TR?= MVO0PIg> MV3heJRmdnWjdHXzJI9VWi2rbnT1Z4VlKGGyb4D0c5Nqew>? NVPqSVROOjJ2NkW4N|M>
HeLa  M3m1N2Fxd3C2b4Ppd{BCe3OjeR?= M{Xm[VUxyqEQvF2= M2H1eVQwQGh? NYDRSW81cW6qaXLpeJMhW1SVLXnu[JVk\WRibHH0[U1xcGG|ZTDhdI9xfG:2aXOg[ZZmdnS| MoTYNlI1PjB3MES=
HeLa  NWfaNmZSSXCxcITvd4l{KEG|c3H5 MYC1NOKh|ryP NYjSWY1LOWh? NYLNVIx4e3WycILld5NmeyC2aHWgSnJCWC2rbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBidm6neHnuJHYheG:|aYTpeoUh[2WubIO= MVOyNlQ1QTR2MB?=
T47D  NWL6[pJESXCxcITvd4l{KEG|c3H5 MVKxNFDPxE1? MYixbC=> NYnsRmI3[myxY3vzJJRp\SCpZX7ldoF1cW:wIH;mJGUu[2GmL1PUSlIh[nliU2TT NFfIeWUzOjRyMUG2PC=>
HeLa  NX[5Z2MzSXCxcITvd4l{KEG|c3H5 MlfzN|DPxE1? NUPnVnY4PGh? NUK4cpZoyqCrbnPy[YF{\XNidHjlJIdmdmW{YXygZ4VtdCC4aXHibYxqfHliNEigbEBi\nSncjDwbI91d2S7bnHtbYMhfHKnYYTt[Y51yqB? MYSyNlM6PDJ2OB?=
HCC MX3BdI9xfG:|aYOgRZN{[Xl? NYrJR4FDOjBizszNxsA> M3XFeFJp NEKzS|JifHSnboXheIV{KHSqZTDETGEhcW6mdXPl[EBi[3SrdnH0bY9vKG:oIGDBVnA> NUi0dGc6OjJ|NEK3N|I>
mESCs MnHhRZBweHSxc3nzJGF{e2G7 NV\xZ2xtOi53zszN NEnI[WMzcA>? MoDObY5pcWKrdIOgeIhmKE6jRj3t[YRq[XSnZDDjZZNx[XOnIHHjeIl3[XSrb36= NU\RZnlmOjJ{OEWyO|Q>
EMT-6  NHLLPWZEgXSxdH;4bYNqfHliQYPzZZk> NGX2NIMyODEQvF2= Ml3lNYg> Mnj4dIFzfGmjbHz5JIJtd2OtZXSgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KHOrcnHt[ZNqdmV? MXeyNlI2OTl{MR?=
MCF7 MkTkRZBweHSxc3nzJGF{e2G7 MWW1NOKh|ryP NWm2UphxOWh? MWDpcohq[mm2czDQRUBi[3SrdnH0[YQh[2G|cHHz[U0{NCBvOTygZY5lKHCxbImoRWRRNXKrYn;z[UkheG:ueX3ldoF{\Q>? M4f1bFIzOjJ|M{S1
K562 NHPp[m1CeG:ydH;zbZMhSXO|YYm= M2\1dVIxKM7:TdMg NYmzUoFFPDiq MkfxSG1UVw>? NH7ZbGJjdG:la4OgcIFx[XSrbnniMYlv\HWlZXSgbY5pcWKrdHnvckBw\iC4aXHibYxqfHliYX7kJIFxd3C2b4Ppd{BqdmS3Y4Tpc44> MYOyNlIyPjF3OB?=
Molt4-hyg MYfBdI9xfG:|aYOgRZN{[Xl? NVvsRpgzOTEQvF2= M4i4VlAvPWh? MmDxZoxw[2u|IH\hdo5me2:uLXnu[JVk\WRiY3HzdIF{\S1|LXzpb4Uh[WO2aY\peJk> NXXVUIgyOjZ{N{W4NVE>
HeLa MlzWRZBweHSxc3nzJGF{e2G7 M{PPc|Ex|ryP MnL2NE42cA>? NXTHTYt3cW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nlidHjlJINwdWKrbnXkJJRz\WG2bXXueEB4cXSqIHfvcYl{cW5iTjDhcoQhXFKDSVy= NV33[nhHOjJzN{m2OlE>
Jurkat T M1jBd2Fxd3C2b4Ppd{BCe3OjeR?= NYXDVYQzOzEQvF2= M17TSFAvPWh? NXW3dWNrTE2VTx?= M4Xm[YJtd2OtczD0bIUhgmm{YX2tbY5lfWOnZDDhdI9xfG:|aYO= M1jHTlIzOTV7OEm4
Neutrophil NITabm1CeG:ydH;zbZMhSXO|YYm= MYmyNO69VQ>? MUOwMlVp NH\RN5RifHSnboXheIV{KHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeEBw\iCPYWKx NGHFWm4zPjF7Nki0OC=>
HCT116 MULBdI9xfG:|aYOgRZN{[Xl? MYq1NOKh|ryP M4PMO|Jp NWDNcGpOemW4ZYLz[ZMhe3mwZYLnbZN1cWNiYYDvdJRwe2m|IHXm[oVkfHNib3[gZ4Vt\WOxeHniJIFv\CCQUFOtNVbDqA>? Mk\sNlIyPTl5NUK=
MDA-MB-231  M1PLWWFxd3C2b4Ppd{BCe3OjeR?= NG\2fXgzNjVvNz61{txO MWGybC=> MnrQbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhib3[gUWRCNU2ELUKzNUBk\WyuczDpcoR2[2WmIHL5JHNFXCCrbjDhJINwdmOnboTyZZRqd25iZHXw[Y5l\W62IH3hco5meg>? NHraSGczOjFzNUWyOi=>
LNCaP MUfBdI9xfG:|aYOgRZN{[Xl? MU[0NO69VQ>? NU\lfYtyOmh? M3SwdYlvcGmkaYTzJIJ2fGWrbjDpcoR2[2WmIHPlcIwh[XCxcITvd4l{ MUWyNlEyPDd4NB?=
MB231 M4Xjd2Fxd3C2b4Ppd{BCe3OjeR?= NIfxe4IyODEQvF2= NVnr[lRiOWh? NXflcWhFTE2VTx?= NVvzZ|d6[WK{b3fheIV{KHSqZTDpcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCkeTDXSWUyKGmwaHnibZRqd25uIGTSRWlNKHS{ZXH0cYVvfCxiYX7kJJRp\SClb33ibY5ifGmxbh?= MU[yNlEyOjl2MB?=
HCC38  MWnBdI9xfG:|aYOgRZN{[Xl? MmDJNVAx|ryP MoD2NYg> MVfEUXNQ NF3lUJJi[nKxZ3H0[ZMhfGinIHnu[JVkfGmxbjDv[kBk\WyuIHTlZZRpKGK7IGfFSVEhcW6qaXLpeIlwdixiVGLBTWwhfHKnYYTt[Y51NCCjbnSgeIhmKGOxbXLpcoF1cW:w NWrZRnp6OjJzMUK5OFA>
MDA-MB231 NGjUNoVCeG:ydH;zbZMhSXO|YYm= MlmwOVDDqM7:TR?= MoHuNlRp NEDhZ3pFVVOR NXzHVIYx[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>? MYSyNlExOTN|NR?=
LNCaP NYPPcWpxSXCxcITvd4l{KEG|c3H5 MkX2OVDDqM7:TR?= MlvnNlRp NXHwUXM6TE2VTx?= MVHhZpJw\2G2ZYOgZ5Vz[3WvaX6tbY5lfWOnZDDj[YxtKGSnYYTo NVH4dGVLOjJzMEGzN|U>
HCT116 NFTMSmxCeG:ydH;zbZMhSXO|YYm= NXPrZ|B1PTEEoN88US=> NWm0bHNsOjSq M3jDeWROW09? MWXhZpJw\2G2ZYOgZ5Vz[3WvaX6tbY5lfWOnZDDj[YxtKGSnYYTo MUKyNlExOTN|NR?=
Ishikawa  MYLBdI9xfG:|aYOgRZN{[Xl? MkPDNlXPxE1? M1rOW|I1cA>? MlfKdoVlfWOnczDj[YxtKGSnYYToJIFv\CCjcH;weI9{cXNiaX7keYNm\CCkeTDCZYYhSTF? M2G0TFIzODh6OUG4
 YD-8  M{PhfmFxd3C2b4Ppd{BCe3OjeR?= NUjzUnF5OTByzszN MVmxbC=> NEDwRphqdmirYnn0d{BRVEWRLXnu[JVk\WRiYYDvdJRwe2m| NHj0bmMzOjB6NkG4Ny=>
eosinophil  MnHuRZBweHSxc3nzJGF{e2G7 NEDJXGU6OM7:TR?= NVWw[ZpLOjSq NXzvO5BycW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliRnHzJIFvfGmkb3T5xsA> MnX0NlIxPzl|M{S=
L929 MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWyMlXPxE1? MoC4NlRp NEWzVXFqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxNXB|ODDhcoQhVkZvzsrCJJRwKGG3Z33lcpQhXE6IzsGtbY5lfWOnZDDu[YNzd3C2b4Ppd{BidmRiYYX0c5Bp[We7 NG[x[WczOjB{N{C5Oy=>
YD-8  NX3HUVE4SXCxcITvd4l{KEG|c3H5 M3r0O|ExOM7:TR?= NXnySFk1OWh? Mlr0Zoxw[2u|IITo[UBIWy2KQ3ytbY5lfWOnZDDhdI9xfG:|aYO= M1;XSVIzODJyMEe4
HBx NF75b2VCeG:ydH;zbZMhSXO|YYm= MoWzNlXPxE1? NXLxdJFvPDiq NFHsVXdFVVOR M2X0[JJm\HWlZXSgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KDNvTVG= NIHoSW4zOjB{MEC3PC=>
U937  NVe2eZRbSXCxcITvd4l{KEG|c3H5 M4rBXVUxyqEQvF2= M3TxN|Fp NHrJd4tqdmirYnn0d{BJTi2rbnT1Z4VlKGGyb4D0c5Nqe8Li MnrENlE6QTh5M{G=
HL60 MXPBdI9xfG:|aYOgRZN{[Xl? MkPqOFDPxE1? M37aTVQxdWmw NXTsPGJMTE2VTx?= NEnv[ZpjdG:la4OgRm5FSyClb33wc5Vv\HNiaX7keYNmKGW6cH;zeZJmKG:oIIDoc5NxcGG2aXT5cJNmemmwZTDhcoQhTE6DIH\yZYdu\W62YYTpc44> M1PiSFIyQTh|Mkm2
M-14 MnXPRZBweHSxc3nzJGF{e2G7 MorFNlXPxE1? M2OzTlAvPWh? M3XSU:KhcW6qaXLpeJMh[m:2aDD0bIUh[3K3ZHWg[Zh1emGldD2gZY5lKGOxbYDveY5lNWmwZIXj[YQh[XCxcITvd4l{ NWnhTVdxOjF7NUS5OVk>
SK-BR-3 MV\BdI9xfG:|aYOgRZN{[Xl? NGP4UIo2OMLizszN MWKybC=> MnfEZoxw[2u|IHHwc5B1d3SrYzDEUmEh\nKjZ33lcpRifGmxbjDpcoR2[2WmIHL5JINwdWKrbnH0bY9vKG:oIGPNMVE3PCCjbnSgdoFlcWG2aX;u MWWyNVkxOTN6Nh?=
MDA-MB-468 M{\3VWFxd3C2b4Ppd{BCe3OjeR?= NWTPR|Y6PTEEoN88US=> NGfROowzcA>? NIPIc3FjdG:la4OgZZBweHSxdHnjJGRPSSCocnHncYVvfGG2aX;uJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25ib3[gV20uOTZ2IHHu[EBz[WSrYYTpc44> NVf6fI5sOjF7MEGzPFY>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
IRF-1 / p-STAT1 / cleaved PARP1 / cleaved-caspase3; 

PubMed: 27191889     


With the addition of Z-VAD-FMK, levels of cleaved Caspase-3 and PARP1 were decreased.

Beclin1 / Atg5 / Atg7 / LC-3I / LC-3II; 

PubMed: 27191889     


Levels of Beclin1, Atg5, Atg7 and LC3-II were decreased after IFN-γ stimulation. However, when IFN-γ was combined with the caspase inhibitor, levels of Beclin1, Atg5, Atg7 and LC3-II were not decreased as determined by the Western Blot test. 

p23 / Hsp90 / hTRET / MMP2; 

PubMed: 19740745     


Expression of Hsp90 client proteins during cell death. HeLa cells were preincubated with z-VAD-fmk (100 μM) for 1 h and exposed to various concentrations of tunicamycin (Tu, in μM) for 24 h. Cell extracts were prepared and analyzed by Western blotting. β-Actin was used as the loading control.

cyto C; 

PubMed: 17301139     


z-VAD-fmk did not inhibit cytochrome c release in RRV-infected MA104 cells (RRV: rhesus rotavirus). Mock- and RRV-infected MA104 cells either were not pretreated or were pretreated with 100 μM z-VAD-fmk for 2 h before RRV infection, and treatment was continued during infection. Fourteen hours after RRV infection, the cytosolic and heavy-membrane fractions were assayed for cytochrome c by Western blotting. Mock-infected MA104 cells were used as negative controls. Cox IV and tubulin were used as protein loading controls for the heavy-membrane and cytosolic fractions, respectively. Positions of molecular weight markers are indicated on the left.

27191889 19740745 17301139
Growth inhibition assay
Cell viability; 

PubMed: 12522090     


Inhibition of magnolol-induced apoptotic cell death by z-VAD-fmk. CH27 cells were treated with cell permeable broad-spectrum caspase inhibitor (z-VAD-fmk) 2 h prior to 80 μm magnolol treatment. Cell viability was estimated. ***P<0.001, compared with the 80 μM magnolol-treated group. 

12522090
Immunofluorescence
cytochrome c ; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Smac/DIABLO; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Endo G; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of EndoG together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

AIF; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of AIF together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

11726499 12941691
ELISA
IL-1β; 

PubMed: 26254306     


Cell-free medium supernatants were harvested at 5 h. IL-1β levels were measured by ELISA. Z-VAD-FMK was used as a positive control. Bars represent means ± sem of pooled results from 3 experiments performed in triplicate at different times.

26254306
In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

+ Expand
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD1 mice
  • Formulation: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID